Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

Research & Clinical Trials > Study Search Tool > Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

| More

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

This study is open to:

Patients are eligible if they have one of the following types of cancer:

  • Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent in adult patients with:
    • Triple-negative breast cancer
    • ER/PR-positive breast cancer
    • Recurrent platinum sensitive ovarian cancer
    • Castration resistant prostate cancer
    • Non-small cell lung cancer
    • Urothelial cancer 
  • Mandatory primary or metastatic tumor biopsy. If archival tumor tissue is available from a biopsy/surgery the tumor tissue may be submitted without repeating a tumor biopsy during the screening period.
This study is not open to:

The following patients are not eligible:

  • Prior treatment with a PARP inhibitor
  • Prior immunotherapy 
  • Prior anti-cancer therapy within 4 weeks prior to study enrollment. Prior radiation therapy within 2 weeks prior to enrollment
  • Major surgery within 4 weeks prior to study enrollment
  • Current use of immunosuppressive medication at the time of study enrollment
  • Patients with known brain metastases requiring steroid
  • Clinically significant cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months prior to study entry; unstable angina, congestive heart failure or a serious cardiac arrhythmia requiring medication.
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Clinicaltrials.gov identifier:
NCT03330405

Treatment:
Breast
Ovarian
Prostate

Study Contact Information

For study information, contact: Pfizer CT.gov Call Center 1-800-718-1021 or by email

About the Study

The purpose of the study is to examine the anti-tumor activity and safety of the immuno-onology agent, Avelumab in combination with the PARP inhibitor, talazoparib in patients with locally advanced  or metastatic triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, castration resistant prostate cancer (CRPC)solid tumors, non-small cell lung cancer (NSCLC), and urothelial cancer (UC).

Type of Study

This is a nonrandomized, open label study. All  participants will receive the study agents, avelumab (intravenous) and talazoparib (oral). 

Study Site

Houston, TX
MD Anderson Cancer Center

FORCE:Facing Our Risk of Cancer Empowered